Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL 37 versus METHADOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL 37 versus METHADOSE.
FENTANYL-37 vs METHADOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a mu-opioid receptor agonist, producing analgesia, sedation, and respiratory depression by activating G-protein coupled opioid receptors in the CNS, leading to inhibition of adenylate cyclase, decreased cAMP, and reduced neurotransmitter release.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
For opioid-naive adults, initial dose 50-100 mcg IV/IM every 1-2 hours as needed for pain; transdermal: 12-25 mcg/h applied every 72 hours for opioid-tolerant patients only. For anesthesia: 2-20 mcg/kg IV as part of balanced anesthesia.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life: 3–7 hours (prolonged in elderly, hepatic impairment, or with continuous infusion due to context-sensitive half-life up to 300 min).
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Renal: ~75% (as metabolites, <10% unchanged); Fecal: ~9%; Biliary: minor.
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Category D/X
Category C
Opioid Agonist
Opioid Agonist